Gene-edited kidney transplant to lower rejection risk
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have end-stage kidney disease and are on the waiting list for a kidney transplant.
- You are between 16 and 85 years old.
- A suitable donor kidney (matching your blood type) is available for the study.
- You are willing to travel to the study center in China for long-term follow-up.
- You are not pregnant or breastfeeding, and agree to use effective birth control.
- You do not have an active infection or other serious health condition that would make transplant unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genes affect long-term kidney transplant health. It aims to understand why some transplanted kidneys fail over time, and may help personalize care for transplant recipients.
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
This study is looking at how genes affect kidney transplant outcomes. It asks you to give extra blood, urine, stool, and kidney tissue samples over time, so researchers can learn more about why some transplants work better than others.
This trial tests a new treatment using your own immune cells, called tolerogenic dendritic cells, to help your body accept a kidney transplant. It is designed for people who are highly sensitized and have a very hard time finding a matching donor kidney.
This study tests a new combination of medicines (Sip-Tego) to help your body accept a living donor kidney without needing lifelong anti-rejection drugs. It is for people with advanced kidney failure who are getting a first or second transplant.
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.